Answer: Antiretroviral drug to treat HIV/AIDS
Notes: The World Health Organization reveals a surge in resistance to the key antiretroviral drug Dolutegravir (DTG) in HIV patients, posing challenges to treatment efficacy. DTG, endorsed by WHO since 2018, is a preferred HIV treatment due to its effectiveness and minimal side effects. Survey data indicates resistance rates between 3.9-8.6%, particularly high in individuals with elevated viral loads transitioning to DTG-based antiretroviral therapy (ART), emphasizing the need for tailored approaches in managing drug resistance.
